Merck halts testing of combination drug for lung cancer treatment 

Merck said on Thursday it was halting a trial of a combination immunotherapy in patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed.

Compartir esta publicacion:

ENTRADAS POPULARES
SÍGANOS
Danos like en facebook
Síganos en Twitter
Suscríbase a nuestro canal
Tik Tok
TRANSMISIÓN EN VIVO